PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.39
5.09M / 4.21M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
-71.04%
Negative gross profit growth while JHX is at 7.45%. Joel Greenblatt would examine cost competitiveness or demand decline.
-95.63%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-95.63%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.04%
Share reduction while JHX is at 0.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.05%
Reduced diluted shares while JHX is at 0.20%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
209.78%
Positive 10Y revenue/share CAGR while JHX is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
37.34%
Positive 5Y CAGR while JHX is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
14.83%
Positive 3Y CAGR while JHX is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.78%
Net income/share CAGR at 50-75% of JHX's 125.71%. Martin Whitman might question if the firm’s product or cost base lags behind.
-42.16%
Negative 5Y net income/share CAGR while JHX is 125.71%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-18.75%
Negative 3Y CAGR while JHX is 125.71%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.85%
3Y equity/share CAGR above 1.5x JHX's 21.53%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.